Analyst ratings and price targets can significantly influence a stock's performance. In this case, EF Hutton, a reputable financial institution, has reiterated a 'Buy' rating on BioAtla, indicating a positive outlook for the company. The maintained price target of $25 also suggests that the analyst believes the stock is undervalued at current levels, which could lead to increased buying pressure and a potential rise in the stock's price in the short term.